Elite Pharmaceuticals Inc (ELTP)

[Bngo]

ELTP is still way undervalued according to this calculation.

Should be at $0.7959 per share even before all these newly revenue to be reported with the recent launches of Methotrexate
(~$63 million market),
Codeine with Acetaminophen
(~$47 million market), and
generic Adderal in Israel.

There will be significantly more revenue from the launches of generic Percocet
(~ $500 million market) around 11/18/24 and
generic Norco
(~$477 million market) right after the new year.

Elite will have awesome news soon with another record breaking quarterly earnings press release on 11/14/24 and the approval of generic Vyvanse hopeful in November 2024
($5.1 billion market).

Casual investors will regret giving up their shares so soon recently.

True long investors with do extremely well with their returns with ELTP when it goes to $5 to $7 within 2 years.


Drug Manufacturers
Specialty & Generic
P/E ratio: 36.96
47 generic companies

ELTP EPS ($0.0191) x Average P/E Ratio by Industry of 47 generic drug manufacturers of (36.96) = Price Per Share ($0.7059)